From our results, we can more confidently conclude that SPDL1 fits well the feature of a double-faced protein, the level of which needs to be tightly regulated in tumors: moderate expression levels associate with a particularly poor prognosis in CRC, while high expression levels with improved prognosis. The gene discussed is SPDL1; the disease is colorectal carcinoma.